IDEAYA Biosciences – Executive Summary

Founded 2015 on the investment thesis that Synthetic Lethality would emerge as a central focus of precision medicine oncology, with significant Pharma interest and the potential to develop *first-in-class* therapeutics for biomarker-defined cancer patient populations.

Broad Pipeline of clinical and preclinical precision medicine oncology programs with defined patient biomarkers, including

- *MAT2A* for patients having tumors with MTAP deletion, a population estimated to represent ~ 15% of all solid tumors,
- *Pol Theta* for patients with tumors having mutations in BRCA or other homologous recombination deficiency,
- *PARG* for patients having tumors with BRCA mutations or other genetic and/or molecular signatures,
- *Werner Helicase* for patients having tumors with high microsatellite instability, and
- *IDE196* for patients having metastatic uveal melanoma (MUM) and other solid tumors harboring GNAQ or GNA11 mutations, such as skin melanoma.

Proven Management Team with deep business and scientific experience has built leading oncology biotech companies, led by CEO Yujiro S. Hata, M.B.A., an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients.

Scientific Advisory Board includes world-class scientists who are key opinion leaders in precision medicine oncology and synthetic lethality, including Alan D'Andrea, M.D. (Harvard, Dana Farber), Bill Sellers, M.D. (Broad Institute, Novartis), and Frank McCormick, Ph.D. (UCSF).

Pharma Strategic Partnerships and Collaborations with GlaxoSmithKline[1] and Pfizer[2]. The GSK strategic partnership validates IDEAYA's Synthetic Lethality platform and is highly accretive to IDEAYA – retaining significant commercial rights and favorable cost share. IDEAYA and GSK will collaborate on three programs – *MAT2A, Pol Theta* and *Werner Helicase.* IDEAYA retains 50% US profit-share and ex-US royalties for *MAT2A* and *Werner Helicase*, and worldwide royalties for *Pol Theta*, with potential to earn up to approximately $3 billion in aggregate cash milestones across the three programs.

Strong Balance Sheet of ~$289 million[3] with capital efficient model is anticipated to fund planned operations into 2024, supporting clinical data milestones across multiple programs, including Phase 1 interim data for development candidate IDE397 in *MAT2A* and potential GSK option exercise (+ $50 million), Phase 1 interim data in *Pol Theta*, Phase 1 initiation in *PARG*, and Phase 1 interim data in *IDE196* monotherapy (MUM) and combination therapy (MUM and other GNAQ/11-mutated tumors, including Skin Melanoma).

Analyst Coverage by JP Morgan, Citi, Jefferies, RW Baird, Oppenheimer, Northland, Roth Capital Partners, HC Wainwright and Wedbush

(1) GSK Collaboration, Option and License Agreement; (2) Pfizer Clinical Trial Collaboration and Supply Agreement: (3) Includes cash, equivalents and marketable securities as of September 30, 2020